88 Donor pretreatment with G-CSF prevents chronic graft-versus-host disease after allogeneic stem cell transplantation  by MacDonald, K.P. et al.
Poster  P resentat ions  - Sess ion  I 
transgenic HSC can engraft and evolve significant numbers of 
antigen specific T-cclls, which may in the future be utilized for 
targeted antigen specific GVL. 
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RESIDUAL HOST CHIMERISM AND PATTERN OF ANTIGEN EXPRES- 
SION INFLUENCE THE FATE OF ADOPTIVELY TRANSFERRED ALLO- 
GENIC T CELLS 
Dzlra/eovic, N.; F:/chs, E.J.; Lz:zJdk, L. The Si,lm 7 RTm::zel Comp're- 
he~zsive Cavce'r CeJl~e:" at ffoh:zs Hopleilzs, B,zlti1~lo:'e, MD. 
Donor lymphocyte infusions (DLI) and allogeneic T cells spe- 
cific for defined lninor histocompatibility antigen (±HAg) are 
increasingly used in the treatment of relapsed malignancies after 
allogeneic BMT. However, the fate and function of adoptively 
transferred T cells are poorly understood. To evaluate the role of 
host chimerism, complete and mixed chimeras were constructed 
by transplanting DBA/2 mice (H-2 d) with bone marrow (BM) 
from MHC-mismatched C56BL/6 (H-2 t') donors after myeloabla- 
tive and non-myeloablative conditioning, respectively. Three 
weeks later, both sets of chimeras received CFSE-labeled B6.SJL 
T ceils, which uniquely express the CD45.1 allele. On day 6 and 
10 after DLI administration, 86% and 93% of CD45.I + T ceils in 
mixed chimeras, respectively, and 41% and 63% of CD45.1 + T 
cells in full donor chimeras, respectively, underwent more than 7 
divisions. Serial monitoring of CD45.1 + T cells in full donor 
chimeras revealed that 28% of these cells remain undivided for 
more than 20 days. To define the effect of targeted antigen tissue 
expression pattern on the fate of allogeneic antigen-specific T 
cells, we used transgenic mice with wide (HA104) or pancreas- 
restricted (Ins-HA) expression of hemaglutinin (HA). TCR trans- 
genic Clone 4 (CL4) mice, which contain H-2K ~1 restricted CD8 + 
T cells specific for HA peptide were used as a source of antigen- 
specific T ceils. HA104 or Ins-HA mice on BALB/c background 
underwent BMT from MHC-compatible B10.D2 donors, fol- 
lowed by DLI from TCR transgenic B10.D2-CL4 mice three 
weeks later. Differential expression of the Thy 1.1 ÷ antigen on 
transgenic T cells was used for in vivo monitoring of their fate. 
Adoptively transferred TCR-specific transgenic CD8 ÷ T-cells 
engrafted, expanded, and then sharply declined and became unde- 
tectable in the mice with wide distribution of targeted HA anti- 
gen. In contrast, transgenic T ceils expanded but remained 
detectable for at least 30 days in the animals with pancreas- 
restricted HA expression without causing diabetes. However, co- 
administration of vaccinia virus expressing HA together with 
transgenic T cells resulted in diabetes. In conclusion, residual host 
chimerism, targeted antigens pattern of expression and antigen 
specific vaccinations have a potential to influence the late of adop- 
tively transferred allogeneic T-cells. 
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DONOR PRETREATMENT WITH G-CSF PREVENTS CHRONIC 
GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL 
TRANSPLANTATION 
z!/lacDol~alcl, I~P.I ; Rowe, V.1; Filippich, C J; CloustoJz, A.D.2; Fe:/'alrl, 
ff.L.S; Hill, G.R3 1. The Quee*zslmzd bzstitzlte of Medical Research, 
B:'isbmze, QLD, Azlst,-alia; 2. UMve'rsity of Qaee*Tslalzd, Bvisbmze, 
OLD, Az:st/:alia; 3. UMversit~, of Michigal~, Amz AT"l, or, ~/II. 
The incidence of extensive chronic GVHD (cGVHD) after 
allogeneic stem cell transplantation with G-CSF mobilised 
peripheral blood stem cell (PBSC) products is increased com- 
pared to that after bone *narrow transplantation a d necessitates 
prolonged, expensive and poorly effective immunosuppressive 
therapy. G-CSF is known to alter T cell function and PBSC 
products contain i0-20 times the number of T cells relative to 
bone marrow grafts, both of which may increase cGVHD. We 
have studied the effects of G-CSF and T cell dose on cGVHD in 
two well-described models manifested by either immune complex 
glomerulonephritis (DBA/2-+B6D2F1) or sclerodermatous 
hepatic and cutaneous fibrosis (Bl0.D2-+Balb/c). The former 
model induces GVHD to major and minor HA and the latter to 
minor HA only. Donor mice were treated with G-CSF (2ug/day) 
or diluent for 6 days and recipient mice were transplanted with 
unseparated donor splenocytes that contained equal numbers of 
T cells. In the immune complex model, 80% of SCT recipients 
that received grafts from control treated onors develop nephrot 
ic syndrome compared to 25% in the recipients of G-CSF treat- 
ed grafts (P<0.01) and mortality was decreased from 45 % to I5 % 
(P<0.05). Donor T cell engraftment and B cell activation (class II 
expression) were equivalent in both groups. The reduction in 
cGVHD following donor G-CSF pretreatment occurred in the 
setting of donor Th2 differentiation manifested by reduced inter- 
feron- 7 and increased IL 4 production with a concomitant 100- 
fold increase in the ratio of IgGl:IgG2c~ auto-antibody titres 
(P<0.05). In the scleroderma model, the effect of a 5-fold escalat- 
ed donor G-CSF T cell dose (G-CSF-high T) was compared to 
the low T cell dose (G-CSF-Iow T and control-low T), to mirror 
the effect of the high T cell doses transferred uring clinical 
peripheral blood stem cell transplantation. Hepatic and cuta- 
neous selni-qnantitative histopathology demonstrate hat sclero- 
dermatous cGVHD, characterised by epidermal thickening, 
fibrosis and procollagen deposition, is associated with high T cell 
doses but not G-CSF and Th2 differentiation per se (see table; 
*P<0.05, **P<0.01 v control). Thus, the limitation of T cell doses 
transferred uring PBSCT should reduce chronic GVHD con> 
pared to BMT, whilst maintaining the b neficial effects on graft 
quality. 
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DELAYED INFUSION OF DONOR CD4+25 + T CELLS CONTROLS 
GRAFT-VERSUS-HOST DISEASE WHILE ALLOWING AN EFFECTIVE 
GRAFT-VERSUS-LEUKEMIA RESPONSE 
Jom, s, S.C. ~; Mm'p,by, G. 2,Ko,r,,gold, R.1 . Thomas Jefferso~z Uzziversi- 
U, Kimmel Grocer blstitzLte, Philadelphia, PA; 2. ffeff'ersml Medical 
College, Dept of A*~atoJT~v, Pathology reed Cell Biolog3,, Philadelphia, PA. 
Following allogeneic hematopoietic cell transplantation (HCT), 
the high inverse correlation between graft-versus-host disease 
(GVIID) and leukemic relapse requires that calculated measures 
be taken to reduce GVHD pathology while retaining the graft- 
versus-leukemia effect (GVL). We sought o determine whether 
donor CD4+CD25 + regulatory T cells could control ongoing 
GVHD, effectively providing a window of time whereby the 
GVIt response is permitted to begin in favor of the elimination of 
residual leukemia ceils, before being brought under regulation to 
prevent he full development of lethal GVHD. Prevention of 
lethal GVHD by infusion of donor CD4+CD25 ÷ "F ceils early 
post-HCT (day 2) could be achieved across an MHC barrier in 
the haploidentical C3H into (B6xC3H)F1 model. However, in 
vitro pre-sensitization f donor CD4+CD25 ÷ T cells to recipient 
type alloantigen with high dose IL 2 was required for successful 
regulation. In contrast, in the minor histocompatabiIity antigen 
(miHA)-disparate, CDS-mediated B I0.BR into CBA GVHD 
model, lethal disease could be completely prevented by a single 
injection of freshly isolated donor CD4+CD25 + T cells, given as 
late as 10 days post-HCT. Of importance, this later regulato W 
effect required a CD4~CD25 + to effector CD8 ratio of only 1:3, 
indicating a strong potential for the delayed infusion of 
CD4+CD25 + T cells to control GVHD across miHA barriers. 
Furthermore, this regulation did not prevent complete and 
durable donor engraftment of the hematopoetic compartment. Of 
most significance, the day 10 infusion of donor CD4+CD25 + T 
cells into CBA HCT recipients that had been challenged with the 
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